Compositions and methods for the treatment of inflammation
AssigneeA.T. Resolve Sarl
InventorsPer Gjorstrup, C. Eric Schwartz
Life of this patent
Estimating the term…
Abstract
The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.
Claims19
A compound of formula I,
- or a pharmaceutically acceptable salt thereof, wherein:
- Re and Rf are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, acyl (e.g., alkoxyacyl, aminoacyl), aminocarbonyl, alkoxycarbonyl, or silyl;
- E is a branched alkoxy;
- Rh and Ri are independently selected from hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, aryl or heteroaryl;
- R5 is selected from i-iv as follows:
- i) CH2CH(R6)CH2, where R6 is hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, aryl, heteroaryl, fluoro, hydroxyl or alkoxy;
- ii) CH2C(R6R7)CH2, where R6 and R7 are each independently alkyl, alkenyl, alkynyl, perfluoroalkyl, aryl, or fluoro, or R6 and R7 are connected together to form a carbocyclic or heterocyclic ring;
- iii) CH2OCH2, CH2C(O)CH2, or CH2CH2;
- or iv) R5 is a carbocyclic, heterocyclic, aryl or heteroaryl ring;
- and
- R8 and R9 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, alkoxy, aryl or heteroaryl, or R8 and R9 are connected together to form a carbocyclic or heterocyclic ring.
A compound represented by formula 1001,
- or a pharmaceutically acceptable salt thereof.
A method of treating or preventing an ophthalmic condition comprising administering a compound represented by formula 1001,
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical preparation comprising a compound represented by formula 1001,
- or a pharmaceutically acceptable salt thereof.
A packaged pharmaceutical for delivering eyedrops to an eye in need of treatment for an ophthalmic condition, wherein the eyedrops comprise a compound represented by formula 1001,
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical preparation suitable for treating or preventing an ophthalmic condition in a human patient, comprising one or more of a compound of any of formulae I-IX, a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound, and one or more pharmaceutically acceptable excipients wherein the pharmaceutical preparation is characterized in that a) the one or more of a compound of any of formulae I-IX, a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound is present in a concentration over 90 micromolar, b) the pharmaceutical preparation is a solution with a pH in the range of 5.5 to 7.4, and/or c) the pharmaceutical preparation further comprises one or more surfactants.
Dependencies are inferred from the claim text.